Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11... | 10 | 1 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 11 | 1 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 12 | 2 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 14 | 2 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 16 | 2 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 18 | 2 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 20 | 6 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 26 | 10 |
| Array BioPharma Inc. | 26 | 1 |
| Astellas Pharma Inc. | 27 | 1 |
| AstraZeneca Plc | 28 | 1 |
| Chiesi Farmaceutici SpA | 29 | 1 |
| Chroma Therapeutics Limited | 30 | 1 |
| Eli Lilly and Company | 31 | 1 |
| GlaxoSmithKline Plc | 32 | 1 |
| Synovo GmbH | 33 | 1 |
| Toray Industries, Inc. | 34 | 1 |
| Zocere, Inc. | 35 | 1 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 36 | 19 |
| ARRY-797 Drug Profile | 36 | 3 |
| AS-1940477 Drug Profile | 39 | 1 |
| CHF-6297 Drug Profile | 40 | 1 |
| CHR-5623 Drug Profile | 41 | 1 |
| losmapimod Drug Profile | 42 | 2 |
| Peptides to Inhibit MAPK14 and MAPK11 for Rheumatoid Arthritis, Multiple Sclerosis and Pancreatic Cancer Drug Profile | 44 | 1 |
| ralimetinib mesylate Drug Profile | 45 | 2 |
| Recombinant Peptide To Inhibit MAPK14 For Ischemic Stroke Drug Profile | 47 | 2 |
| Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease Drug Profile | 49 | 1 |
| Small Molecule to Inhibit p38 MAP Kinase for Undisclosed Indication Drug Profile | 50 | 1 |
| Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases Drug Profile | 51 | 1 |
| SYD-003 Drug Profile | 52 | 1 |
| VX-745 Drug Profile | 53 | 2 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 55 | 6 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 61 | 2 |
| Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.1... | 63 | 12 |
| Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress | 63 | 1 |
| Aug 20, 2016: Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress | 64 | 1 |
| Dec 16, 2015: EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor | 64 | 1 |
| Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study) | 65 | 1 |
| Jul 15, 2015: Zocere's Brain Saving Drug Issued U.S. Patent | 65 | 1 |
| Jun 03, 2015: EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease | 66 | 1 |
| Jan 07, 2015: Zocere to Present Brain-Protecting Drug at Biotech Showcase | 67 | 1 |
| Oct 14, 2014: Zocere Showcases Brain Saving Drug at Life Sciences Summit in New York City | 67 | 1 |
| Oct 01, 2014: Zocere s Stroke Drug to Be Featured at BIO Investor Forum | 68 | 1 |
| Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome | 68 | 1 |
| Nov 06, 2012: Array BioPharma To Present Phase II Results Of ARRY-797 At 2012 American College Of Rheumatology Annual Meeting | 69 | 1 |
| Jul 31, 2012: Array BioPharma's Osteoarthritis Drug Meets Primary Endpoint In Phase II Trial | 70 | 1 |
| Jul 08, 2009: Array BioPharma Announces Top-Line Results In Two Phase I Clinical Trials | 71 | 1 |
| Oct 26, 2008: Array BioPharma's Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit and Systemic Anti-Inflammatory Activity in a Phase II Trial | 72 | 1 |
| May 07, 2008: Array BioPharma Presents Additional Positive Phase II Results Of ARRY-797 In Inflammatory Pain Clinical Trial At The American Pain Society's Annual Scientific Meeting | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |